SCHEMBL2679147

SCHEMBL2679147

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1NC(=O)C=Cc1cccnc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 4/20 0.73
DDR1 Q08345 2/20 0.65
DDR2 Q16832 2/20 0.65
KIT P10721 2/20 0.65
MAPK14 Q16539 2/20 0.65
LCK P06239 1/20 0.65
SRC P12931 1/20 0.65
BRAF P15056 4/20 0.64
KDR P35968 1/20 0.64
HTT P42858 1/20 0.59
MEN1 O00255 1/20 0.58
TSHR P16473 1/20 0.58
KMT2A Q03164 1/20 0.58
KDM4E B2RXH2 3/20 0.57
POLB P06746 3/20 0.57
MAPT P10636 2/20 0.57
APEX1 P27695 1/20 0.57
EPHB2 P29323 1/20 0.56
NAMPT P43490 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10077740 1.00 CSF1R (0.73) CSF1RDDR1DDR2KITMAPK14
SCHEMBL10054791 0.93 BRAF (0.75) CSF1RDDR1DDR2KITMAPK14
SCHEMBL2679153 0.93 BRAF (0.75) CSF1RDDR1DDR2KITMAPK14
SCHEMBL2679952 0.93 CSF1R (0.62) CSF1RDDR1DDR2KITMAPK14
SCHEMBL2679211 0.91 MAPK14 (0.75) CSF1RDDR1DDR2KITMAPK14
SCHEMBL10078414 0.91 MAPK14 (0.75) CSF1RDDR1DDR2KITMAPK14
SCHEMBL10054901 0.89 NAMPT (0.60) CSF1RDDR1DDR2KITMAPK14
SCHEMBL10077755 0.89 CSF1R (0.57) CSF1RDDR1DDR2KITBRAF
SCHEMBL2679206 0.89 CSF1R (0.57) CSF1RDDR1DDR2KITBRAF
Bromomethane SCHEMBL2679140 0.88 BRAF (0.59) CSF1RDDR1DDR2KITMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US claimed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US claimed
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR CSF1R 2608/4885DDR1 330/4885DDR2 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.